Caribou Biosciences
Biotechnology company focused on genome engineering and developing technology-based solutions for cells.
Launch date
Employees
Market cap
€174m
Enterprise valuation
(€39m) (Public information from Sep 2024)
Share price
$2.08 CRBU
Berkeley California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 12.4m | 9.6m | 13.9m | 34.5m | 12.4m | 12.8m | 73.2m |
| % growth | 114 % | (22 %) | 44 % | 149 % | (64 %) | 3 % | 470 % |
| EBITDA | (34.5m) | (68.2m) | (106m) | (113m) | (176m) | (207m) | (63.5m) |
| % EBITDA margin | (279 %) | (710 %) | (767 %) | (326 %) | (1418 %) | (1614 %) | (87 %) |
| Profit | (34.3m) | (66.9m) | (99.4m) | (102m) | (159m) | (207m) | (224m) |
| % profit margin | (278 %) | (697 %) | (718 %) | (296 %) | (1283 %) | (1610 %) | (307 %) |
| EV / revenue | - | 94.6x | 27.7x | 14.7x | 15.7x | 15.2x | 2.7x |
| EV / EBITDA | - | -13.3x | -3.6x | -4.5x | -1.1x | -0.9x | -3.1x |
| R&D budget | 34.4m | 52.3m | 82.2m | 112m | - | - | - |
| R&D % of revenue | 278 % | 544 % | 594 % | 325 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $150k | Grant | |
$2.9m | Series A | ||
$11.5m | Series A | ||
$30.0m | Series B | ||
$30.1m | Series B | ||
| $115m | Series C | |
| N/A | $304m Valuation: $907m 73.4x EV/LTM Revenues -26.3x EV/LTM EBITDA | IPO | |
* | N/A | $125m | Post IPO Equity |
| Total Funding | €172m | ||
Related Content
Recent News about Caribou Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Caribou Biosciences
Edit
exited